Glaukos Corp

  • Earnings Score
  • Moat Score
  • Market Cap $4.91B
  • PE -40
  • Debt -
  • Cash $118.99M
  • EV -
  • FCF -$53.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$123.68M
EBIT-$101.12M
ROE-16%
ROA-10%
FCF-$53.24M
Equity$763.96M
Growth Stability-15K%
PE-39.71
PB6.43
P/FCF-92.24
P/S12.14
Price/Cash0.02
Net Margins-17%
Gross Margins76%
Op. Margins-25%
Earnings CAGR0%
Sales Growth YoY25%
Sales Growth QoQ1%
Sales CAGR15%
FCF CAGR0%
Equity CAGR27%
Earnings Stability0.01
Earnings Growth YoY-56%
Earnings Growth QoQ-46%
Sales CAGR 5Y11%
Equity CAGR 5Y-0%
Earnings CAGR 3Y14%
Sales CAGR 3Y14%
Equity CAGR 3Y14%
Market Cap$4.91B
Revenue$404.52M
Assets$966.18M
Cash$118.99M
Shares Outstanding56.64M
Earnings Score6%
Moat Score4%
Working Capital376.02M
Current Ratio6.49
Gross Profit$306.44M
Shares Growth 3y6%
Equity Growth QoQ-0%
Equity Growth YoY69%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

SEC Filings

Direct access to Glaukos Corp (GKOS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Glaukos Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Glaukos Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability 1%
loading chart...

Glaukos Corp Discounted Cash Flow

Fully customizable DCF calculator online for Glaukos Corp.

= -$548M
012345678910TV
fcf-$53M-$53M-$54M-$54M-$54M-$54M-$55M-$55M-$55M-$55M-$55M-$555M
DCF-$49M-$44M-$41M-$37M-$34M-$31M-$28M-$26M-$23M-$21M-$214M
Value-$548M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-53%4%-0%-7%7%-53%-17%-35%-43%-38%-17%
ROA-3%0%-6%-6%-12%-3%-8%-14%-13%-10%
ROE-4%-0%-7%2%-18%-8%-19%-29%-19%-16%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF------6.33-12.13-4.44-3.63--
Debt over Equity0.2----0.280.480.530.61--
Growth Stability------15K%-----15K%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-60%39%14%31%-5%31%-4%11%22%11%
Earnings YoY growth--112%-102%14K%-219%-880%-59%100%36%9%-
Equity YoY growth-23%18%26%287%-1%-12%-10%-13%66%-0%
FCF YoY growth--297%218%-55%-160%488%-23%175%23%-13%-